News & Events
31 August 2010 Joint services alliance with Jubilant Biosys
15 June 2010 Validation results
24 March 2010 Biotech Info, 24 March 2010
16 March 2010 Collaboration with Sareum, the ICR and CRT
30 November 2009 Completion of Placing
1 October 2009 Trading Update
23 June 2009 Update on EC funded TEMPO project – Achievement of Milestone
Predict Drug Schedules and Combinations
.jpg)
The Physiomics Virtual Tumour can show and predict how a tumour will respond to drug exposure. This integrated PK/PD simulation platform is ideal to optimise drug dosing and scheduling, and design new combination chemotherapy therapies. It can be calibrated and used for proprietary drugs, as well as with our precalibrated standard-of-care agent library.
Simulate Drug Effects with ModelPlayer
.jpg)
Physiomics ModelPlayer™ is a stand-alone application that runs our cell population models. We can provide tailored versions to our partners, allowing them to simulate the effect of their drugs, and design novel drug schedules and combination therapies.
Physiomics PLC
Download Physiomic’s
2009 Annual Report
Physiomics service and technology is absolutely superb, we (ValiRx) have just had some work carried out and it has saved us very significant amounts of development money and time. This is the first time the research has been done this way… George Morris, Chief Development Officer of ValiRx